KYMR Kymera Therapeutics, Inc.
Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Kymera Therapeutics, Inc. (KYMR) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: Strategic discontinuations of KT-295 and KT-474 programs in mid-2025 reduce pipeline breadth and may delay development timelines
- • Updated risk: Increased operating expenses and net loss of $224.4M for nine months ended Sept 30, 2025 vs $153.1M prior year due to advancing clinical activities
Quarterly Financial SummaryXBRL
Revenue
$3M
Net Income
-$82M
Operating Margin
-3346.1%
Net Margin
-2972.0%
ROE
-8.7%
Total Assets
$1.1B
Source: XBRL data from Kymera Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Kymera Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.